Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Glesatinib - Mirati Therapeutics

Drug Profile

Glesatinib - Mirati Therapeutics

Alternative Names: MGCD-265

Latest Information Update: 07 May 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator MethylGene
  • Developer MethylGene; Mirati Therapeutics
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Axl receptor tyrosine kinase inhibitors; Fms-like tyrosine kinase 3 inhibitors; Proto-oncogene protein c-met inhibitors; RON protein inhibitors; TIE 2 receptor antagonists; Vascular endothelial growth factor receptor 3 antagonists; Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Non-small cell lung cancer
  • Discontinued Head and neck cancer; Solid tumours

Most Recent Events

  • 30 Apr 2024 Mirati Therapeutics terminates a phase II trial in Non-small cell lung cancer (Metastatic disease, Late-stage disease, Second-line therapy or greater, Inoperable/Unresectable) in Australia, Canada, Hungary, Italy, Poland, South Korea, Taiwan, the UK and USA (PO) due to modest clinical activity (NCT02544633) (EudraCT2015-002070-21)
  • 22 Apr 2024 Mirati Therapeutics terminates a phase-II trial in Non-small cell lung cancer (Late-stage disease, Metastatic disease, Combination therapy) in USA (PO) due to sponsor portfolio reprioritisation as of April 2024 (NCT02954991)
  • 23 Jan 2024 Mirati Therapeutics has been acquired by Bristol-Myers Squibb
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top